132 related articles for article (PubMed ID: 38349262)
1. Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment.
Vagaggini C; Petroni D; D'Agostino I; Poggialini F; Cavallini C; Cianciusi A; Salis A; D'Antona L; Francesconi V; Manetti F; Damonte G; Musumeci F; Menichetti L; Dreassi E; Carbone A; Schenone S
Drug Dev Res; 2024 Feb; 85(1):e22158. PubMed ID: 38349262
[TBL] [Abstract][Full Text] [Related]
2. Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Nešović M; Divac Rankov A; Podolski-Renić A; Nikolić I; Tasić G; Mancini A; Schenone S; Pešić M; Dinić J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545852
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[3,4-
Kostić A; Jovanović Stojanov S; Podolski-Renić A; Nešović M; Dragoj M; Nikolić I; Tasić G; Schenone S; Pešić M; Dinić J
Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34209342
[TBL] [Abstract][Full Text] [Related]
4. Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-
Jovanović Stojanov S; Kostić A; Ljujić M; Lupšić E; Schenone S; Pešić M; Dinić J
Life (Basel); 2022 Sep; 12(10):. PubMed ID: 36294938
[TBL] [Abstract][Full Text] [Related]
5. Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells.
Monteleone L; Marengo B; Musumeci F; Grossi G; Carbone A; Valenti GE; Domenicotti C; Schenone S
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890294
[TBL] [Abstract][Full Text] [Related]
6. Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.
Vignaroli G; Iovenitti G; Zamperini C; Coniglio F; Calandro P; Molinari A; Fallacara AL; Sartucci A; Calgani A; Colecchia D; Mancini A; Festuccia C; Dreassi E; Valoti M; Musumeci F; Chiariello M; Angelucci A; Botta M; Schenone S
J Med Chem; 2017 Jul; 60(14):6305-6320. PubMed ID: 28650650
[TBL] [Abstract][Full Text] [Related]
7. Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme.
Checa-Chavarria E; Rivero-Buceta E; Sanchez Martos MA; Martinez Navarrete G; Soto-Sánchez C; Botella P; Fernández E
Mol Pharm; 2021 Apr; 18(4):1558-1572. PubMed ID: 33645231
[TBL] [Abstract][Full Text] [Related]
8. Development of Pyrazolo[3,4-
Greco C; Taresco V; Pearce AK; Vasey CE; Smith S; Rahman R; Alexander C; Cavanagh RJ; Musumeci F; Schenone S
ACS Med Chem Lett; 2020 May; 11(5):657-663. PubMed ID: 32435367
[TBL] [Abstract][Full Text] [Related]
9. Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-
Poggialini F; Vagaggini C; Brai A; Pasqualini C; Crespan E; Maga G; Perini C; Cabella N; Botta L; Musumeci F; Frosini M; Schenone S; Dreassi E
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839775
[TBL] [Abstract][Full Text] [Related]
10. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-
Fallacara AL; Zamperini C; Podolski-Renić A; Dinić J; Stanković T; Stepanović M; Mancini A; Rango E; Iovenitti G; Molinari A; Bugli F; Sanguinetti M; Torelli R; Martini M; Maccari L; Valoti M; Dreassi E; Botta M; Pešić M; Schenone S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248184
[TBL] [Abstract][Full Text] [Related]
11. Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line.
Cammarata FP; Torrisi F; Forte GI; Minafra L; Bravatà V; Pisciotta P; Savoca G; Calvaruso M; Petringa G; Cirrone GAP; Fallacara AL; Maccari L; Botta M; Schenone S; Parenti R; Cuttone G; Russo G
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554327
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.
Vignaroli G; Zamperini C; Dreassi E; Radi M; Angelucci A; Sanità P; Crespan E; Kissova M; Maga G; Schenone S; Musumeci F; Botta M
ACS Med Chem Lett; 2013 Jul; 4(7):622-6. PubMed ID: 24900720
[TBL] [Abstract][Full Text] [Related]
13. The Pyrazolo[3,4-
Rango E; Pastorino F; Brignole C; Mancini A; Poggialini F; Di Maria S; Zamperini C; Iovenitti G; Fallacara AL; Sabetta S; Clementi L; Valoti M; Schenone S; Angelucci A; Ponzoni M; Dreassi E; Botta M
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327462
[TBL] [Abstract][Full Text] [Related]
14. Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.
Calgani A; Vignaroli G; Zamperini C; Coniglio F; Festuccia C; Di Cesare E; Gravina GL; Mattei C; Vitale F; Schenone S; Botta M; Angelucci A
Mol Cancer Ther; 2016 Jul; 15(7):1535-44. PubMed ID: 27196762
[TBL] [Abstract][Full Text] [Related]
15. Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.
Svec RL; Furiassi L; Skibinski CG; Fan TM; Riggins GJ; Hergenrother PJ
ACS Chem Biol; 2018 Nov; 13(11):3206-3216. PubMed ID: 30296373
[TBL] [Abstract][Full Text] [Related]
16. Self-assembling and self-formulating prodrug hydrogelator extends survival in a glioblastoma resection and recurrence model.
Schiapparelli P; Zhang P; Lara-Velazquez M; Guerrero-Cazares H; Lin R; Su H; Chakroun RW; Tusa M; Quiñones-Hinojosa A; Cui H
J Control Release; 2020 Mar; 319():311-321. PubMed ID: 31911154
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
[TBL] [Abstract][Full Text] [Related]
18. SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines.
Torrisi F; Minafra L; Cammarata FP; Savoca G; Calvaruso M; Vicario N; Maccari L; Pérès EA; Özçelik H; Bernaudin M; Botta L; Russo G; Parenti R; Valable S
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486205
[TBL] [Abstract][Full Text] [Related]
19. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract][Full Text] [Related]
20. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
